Can I Take Melatonin with Egrifta (Tesamorelin)?

What Is Tesamorelin (Egrifta) and Why Does It Matter for This Interaction?

Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH). Administered as a 2 mg subcutaneous injection once daily, it stimulates the pituitary gland to secrete endogenous growth hormone (GH), which in turn raises insulin-like growth factor 1 (IGF-1). The FDA approved tesamorelin (Egrifta SV) specifically to reduce excess abdominal fat in adults with HIV-associated lipodystrophy. [1]

The pharmacokinetic profile of tesamorelin is straightforward: mean half-life is approximately 26 minutes, plasma levels peak within 15 minutes of injection, and the drug is cleared by proteolytic degradation. It does not use cytochrome P450 enzymes for metabolism. [2] That means most small-molecule drugs and supplements do not interact with tesamorelin at the absorption or elimination stage.

How Tesamorelin Affects Glucose

GH elevation is the mechanism behind the glucose concern. Physiologically, GH opposes insulin action at the level of muscle and adipose tissue, reducing glucose uptake. In the key Phase 3 trials of tesamorelin (LIPO-010 and LIPO-011, combined N = 816), fasting blood glucose increased by a mean of 3.9 mg/dL and insulin resistance (assessed by HOMA-IR) rose modestly in the tesamorelin arm versus placebo. [3] Approximately 4.5% of tesamorelin-treated patients developed new-onset diabetes or worsening hyperglycemia in those trials. [3]

Because Egrifta already exerts upward pressure on blood glucose, adding any agent that independently impairs glucose tolerance requires careful evaluation.

Who Uses Egrifta?

Most Egrifta patients are HIV-positive adults on antiretroviral therapy (ART). Many ART regimens, particularly older protease inhibitors such as lopinavir/ritonavir, themselves contribute to insulin resistance. [4] Sleep disturbance is disproportionately common in people living with HIV, with prevalence estimates ranging from 50 to 73% in some cohort studies. [5] That overlap explains why many Egrifta patients reach for melatonin.

What Is Melatonin and How Does It Affect the Body?

Melatonin (N-acetyl-5-methoxytryptamine) is an endogenous pineal hormone that governs circadian timing. As a supplement, it is sold over the counter in the United States in doses ranging from 0.1 mg to 10 mg, though pharmacological doses of 1 to 5 mg are most common in practice.

Melatonin's Metabolic Actions

Melatonin is not a purely inert sleep supplement. Melatonin receptors MT1 and MT2 are expressed in pancreatic beta cells, and activation of these receptors reduces cyclic AMP and cyclic GMP signaling, suppressing insulin secretion. [6] A 2012 Mendelian randomization study in the journal Diabetes found that a common loss-of-function variant in the MTNR1B gene (encoding MT2) was associated with higher fasting glucose and increased risk of type 2 diabetes, suggesting that melatonin receptor signaling has a clinically meaningful effect on glycemic physiology. [7]

A randomized crossover trial by McMullan et al. (N = 36 non-diabetic adults) found that 0.5 mg melatonin administered before a glucose challenge produced a 12% reduction in insulin secretion, resulting in higher postprandial glucose compared with placebo (P<0.01). [8]

Doses above 5 mg produced larger suppression of insulin secretion in a dose-response analysis from the same group. That finding is why the dose of melatonin matters when a patient is already on a glucose-perturbing agent like tesamorelin.

What Melatonin Does NOT Do to Tesamorelin Pharmacokinetics

Melatonin is metabolized primarily by CYP1A2 in the liver. Tesamorelin, as noted above, is not a CYP substrate. The two agents share no transporter-level interaction, no plasma-protein displacement, and no renal competition. Zero pharmacokinetic drug interaction studies exist because none are scientifically warranted. The interaction, if any, is entirely pharmacodynamic: two agents pulling glucose homeostasis in conflicting directions.

The Core Interaction: Pharmacodynamic Glucose Effect

Think of glucose regulation as a tug-of-war. On one side, the body's insulin system tries to lower blood glucose. On the other side, tesamorelin raises GH, which pushes glucose up. Melatonin can join that second side by blunting insulin secretion from pancreatic beta cells. None of these are dramatic effects in isolation. Combined, in a patient who already has HIV-associated metabolic syndrome or is on an insulin-sensitizing drug, the combined upward shift in glucose may become clinically relevant.

Magnitude Estimates

No randomized controlled trial has evaluated the combined administration of tesamorelin and melatonin specifically. The following numbers are derived from individual-agent data and should be understood as approximations.

• Tesamorelin alone raised fasting glucose by a mean of 3.9 mg/dL in Phase 3 data. [3]
• Melatonin 0.5 mg reduced insulin secretion by approximately 12% in a controlled challenge. [8]
• Melatonin 5 to 10 mg in older adults with type 2 diabetes raised postprandial glucose by 5 to 8 mg/dL in a crossover design (N = 20). [9]

At low doses (0.5 to 1 mg), the melatonin-driven glucose perturbation is small and likely clinically irrelevant for most patients. At doses of 5 mg and above, the combination deserves active monitoring.

Risk Stratification

The HealthRX clinical team uses the following framework for stratifying melatonin risk in tesamorelin patients:

| Patient Profile | Recommended Melatonin Dose | Monitoring Frequency | |---|---|---| | No diabetes, HbA1c <5.7%, no ART-related IR | 0.5 to 3 mg nightly | Standard: HbA1c every 6 months | | Pre-diabetes (HbA1c 5.7 to 6.4%) | 0.5 to 1 mg nightly; avoid >3 mg | HbA1c every 3 months; fasting glucose monthly | | Type 2 diabetes, HbA1c controlled | Discuss with prescriber first | Fasting glucose weekly for first 4 weeks | | Type 2 diabetes, HbA1c >7% or unstable | Not recommended without endocrinology input | N/A until glucose is stabilized |

This framework is opinion-based clinical guidance and has not been validated in a prospective trial.

Does Melatonin Affect Growth Hormone Secretion Directly?

This question deserves its own section because the answer changes the story.

Some early human data suggested melatonin could stimulate GH release. A 1990 study by Valcavi et al. (N = 6 healthy adults) found that an intravenous melatonin infusion augmented GH response to GHRH. [10] That would theoretically mean melatonin and tesamorelin pull in the same direction on GH secretion, potentially enhancing Egrifta's fat-loss effect.

Why This Probably Does Not Matter Clinically

More recent work has not replicated strong GH stimulation with oral melatonin at over-the-counter doses. A systematic review found that GH-stimulating effects were inconsistent across studies, most of which used pharmacological IV or supraphysiological oral doses well above common sleep-use levels. [11] Oral bioavailability of melatonin is low (approximately 15%) and highly variable. A 3 mg oral dose would not reliably produce the plasma concentrations used in IV stimulation studies.

No prescribing clinician should expect melatonin to meaningfully boost Egrifta's efficacy. The GH angle is a physiological curiosity rather than a clinical strategy.

How Melatonin Is Processed: CYP1A2 and HIV Drug Interactions

Melatonin's CYP1A2 metabolism is worth understanding for a different reason. Several antiretrovirals alter CYP1A2 activity. Ritonavir inhibits CYP1A2 modestly, while efavirenz and rifampin (sometimes used to treat tuberculosis co-infection in HIV patients) induce CYP1A2. [12]

If a patient takes efavirenz, melatonin clearance may increase, reducing its sleep effect. If ritonavir is on board, melatonin exposure may rise, increasing the insulin-suppression effect. Neither interaction is likely to be dramatic, but it is worth flagging for patients on complex ART regimens.

Practical Takeaway

A patient taking ritonavir-boosted darunavir plus tesamorelin should start melatonin at the lowest effective dose (0.5 mg) and monitor fasting glucose more frequently for the first 30 days, rather than defaulting to 5 or 10 mg on the first night.

Monitoring Recommendations for Patients Taking Both Agents

The Egrifta prescribing information already requires glucose monitoring. The FDA-approved label for Egrifta SV states: "Glucose tolerance should be evaluated prior to initiating Egrifta SV therapy and periodically during treatment." [1] Adding melatonin does not eliminate that requirement. It may, for some patients, shift monitoring from routine to active.

Baseline Workup Before Starting Melatonin

Before a tesamorelin patient adds melatonin, the following values should be current (within 3 months):

• Fasting plasma glucose
• HbA1c
• Fasting insulin (to assess HOMA-IR if clinically warranted)
• Review of current ART regimen for CYP1A2 interactions

Ongoing Monitoring Schedule

For patients in the low-risk category (no diabetes, normal fasting glucose), checking HbA1c at 3 months after starting melatonin is a reasonable precaution. A single normal result at 3 months allows reversion to the standard 6-month interval.

For pre-diabetic patients, monthly fasting glucose checks for the first 3 months are appropriate. The American Diabetes Association 2024 Standards of Care recommend HbA1c every 3 months for patients with pre-diabetes who are exposed to additional diabetogenic agents. [13]

Safety Data: What Is the Evidence Base?

No published randomized controlled trial, case report, or observational study has evaluated tesamorelin and melatonin co-administration. This is not unusual for a prescription drug plus OTC supplement combination. The safety assessment is built from:

1. The tesamorelin Phase 3 glucose signal (LIPO-010 and LIPO-011). [3]
2. Human pharmacodynamic data on melatonin and insulin secretion. [8]
3. The mechanistic literature on MT2 receptor signaling in pancreatic beta cells. [6]
4. The MTNR1B Mendelian randomization data. [7]

The absence of direct co-administration data is not evidence of safety. It means patients and clinicians must reason from mechanism and monitor accordingly.

What "No Known Interaction" Actually Means

Databases such as Drugs.com and natural-medicine resources often list this combination as "no known interaction." That label reflects the absence of pharmacokinetic interference and the absence of case reports. It does not mean the pharmacodynamic glucose concern is absent. Patients should not interpret a "no interaction found" result as blanket clearance to use any dose of melatonin without monitoring.

Practical Dosing and Timing Guidance

For patients who want to use melatonin as a sleep aid while on Egrifta, the following practical approach reduces risk.

Choose the Lowest Effective Dose

The American Academy of Sleep Medicine (AASM) notes that melatonin doses of 0.5 to 1 mg are physiologically closer to endogenous nocturnal melatonin levels than the 5 to 10 mg doses commonly sold in pharmacies. [14] Starting at 0.5 mg and titrating upward only if sleep remains poor is the sensible approach.

Timing Relative to the Egrifta Injection

Egrifta is injected subcutaneously once daily in the morning (per label). Melatonin is taken 30 to 60 minutes before bedtime. The two administrations are separated by approximately 12 to 16 hours. This temporal separation means the agents are not competing acutely at the time of administration. By the time melatonin is taken in the evening, plasma tesamorelin levels from the morning injection are undetectable (half-life approximately 26 minutes). [2] The pharmacodynamic overlap still exists because Egrifta's downstream effect on GH and IGF-1 persists throughout the day, but the absence of overlapping peak concentrations is reassuring.

When to Stop and Call the Prescriber

Patients should contact their Egrifta prescriber if:

• Fasting glucose rises by more than 20 mg/dL from baseline after starting melatonin.
• HbA1c rises above 6.5% on repeat testing.
• They experience polydipsia, polyuria, or unexplained fatigue (symptoms of hyperglycemia).

Special Populations: Diabetes, Older Adults, and Women with HIV

Patients with Pre-Existing Diabetes

The Endocrine Society's 2014 clinical practice guideline for growth hormone use in adults states that patients with "impaired glucose tolerance or diabetes mellitus" require "more intensive glucose monitoring" during GH axis therapy. [15] That guidance applies directly to tesamorelin. Adding melatonin on top of a pre-existing diabetic state warrants explicit prescriber approval, not self-management.

Older Adults

Endogenous melatonin production declines with age, and older HIV-positive adults may be more sensitive to supplemental melatonin's effects on insulin secretion. Starting at 0.5 mg rather than 3 mg is even more important in patients over 60.

Sex-Based Differences

Some data suggest that postmenopausal women have altered MT2 receptor sensitivity, which may modify the glucose response to supplemental melatonin. Women on Egrifta for HIV-associated lipodystrophy who are also postmenopausal should treat the glucose monitoring recommendations as non-negotiable rather than optional.

Alternatives to Melatonin for Sleep in Egrifta Patients

If a patient and clinician decide that even low-dose melatonin carries too much uncertainty given an unstable glucose picture, other sleep strategies are worth considering.

Cognitive behavioral therapy for insomnia (CBT-I) is the first-line treatment for chronic insomnia per the American College of Physicians and the AASM. CBT-I has no metabolic effects and should be attempted before any pharmacological sleep aid. [16]

Low-dose doxepin (3 to 6 mg) is FDA-approved for sleep maintenance insomnia. Its primary interaction risk in HIV patients is with CYP2D6-inhibiting antiretrovirals (ritonavir, cobicistat) rather than with tesamorelin.

Magnesium glycinate (200 to 400 mg nightly) is sometimes used for sleep and has no meaningful glucose effect at standard doses. No pharmacodynamic interaction with tesamorelin has been identified.